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Background. There are only a few trials for the very elderly population (>79 years). No consen-
sus, which blood pressure (BP) goals and substances should be applied, has been found yet. This
survey was undertaken to investigate how octogenarians are treated and attain BP targets in the
Swiss primary care.
Methods. Data from 4594 hypertensive patients were collected within 7 days. Eight hundred and
seventy-seven patients met the requirement to be >79 years. We assessed substances/combina-
tions and investigated pulse pressure and target blood pressure attainment (TBPA) using three
different recommendations [Canadian Hypertension Education Program (CHEP), Swiss Society
of Hypertension (SSH), European Society of Hypertension-European Society of Cardiology (ESH-
ESC)]. Secondarily, we compared TBPA attained by angiotensin-converting enzyme inhibitor
(ACEI)/diuretic (D), angiotensin receptor blocker (ARB)/D and calcium channel blocker (CCB)/Dwith
any other dual therapy and investigated whether Ds/beta-blockers (BBs) or Ds/renin angiotensin-
converting enzyme inhibitors (RAAS-Is) lead to higher TBPA. Finally, we assessed the impact of
drug administration, practical work experience, location and specialization of GPs on TBPA.
Results. Octogenarians attained target blood pressure (TBP) between 44% (ESH-ESC) and 74%
(SSH). Optimal/normal BP was reached in 22.8% of patients. Pulse pressure <65 mmHg was
shown in 66.4% of patients. Monotherapy was most commonly applied followed by dual single-
pill combinationwith ARB/D (46.5%) or ACEI/D (36.0%). No benefit in TBPAwas found comparing
a RAASI/D and CCB/D treatment with any other dual combination. There was also no difference
between BB/D and RAAS-I/D combination therapy and between single-pill combination and dual
free combinations.
Conclusions. GPs adhere to the use of substances proven in outcome trials and attain high TBP.
No difference inmeeting BP goals could be found using different drug classes. There is an unmet
need to harmonize recommendations and to add additional information for the treatment of
octogenarians.
Keywords. Europe, guidelines, hypertension, octogenarians, Switzerland, target blood pressure
attainment.
Introduction
Hypertension in the very elderly
Due to the increase of life expectation, cardiovascular
late effects shift to high age. Although in 2050 approxi-
mately one-fifth of the ‘older patients’ will be >80 years
and >60% of patients <65 years have hypertension,
there are only a few trials that address this special pop-
ulation. Isolated systolic hypertension (ISH) occurs in
a large number of older patients. Starting at the age of
60 years, systolic blood pressure (BP) is more related
to neurovascular and cardiovascular events than the
diastolic BP. The National Health and Nutrition Exam-
ination Survey confirmed that 75% of patients did not
reach their target blood pressure (TBP) because of
a failure to accomplish systolic goals.1
Recommendations of guidelines
Comprehensive treatment advice is lacking for the
very elderly. Because no difference in the outcome by
the use of certain substances could be shown2 and
the results of STOP-23 were indifferent, all substance
classes are mentioned to be equally effective regard-
less of age. However, confirmation occurred for the
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superiority of diuretics over beta-blockers (BBs) in re-
ducing cardiovascular end points.4,5 Recent data from
the HYpertension in the Very Elderly Trial (HY-
VET)6 provided new evidence in favour of diuretics
and angiotensin-converting enzyme inhibitors
(ACEIs). Thus, this combination might currently con-
stitute the optimal treatment approach (Table 2). For
patients with ISH, VALUE7 showed benefits for the
combination calcium channel blocker (CCB)/diuretic.
Therefore, according to ESH–ESC,8 both substances
are preferred for this special patient population.
Although in 20039 and 2007,8 the ESH–ESC recom-
mended to lower systolic BP <140 mmHg in patients
>65 years, there was no advice for patients >79 years
(octogenarians+). The results of HYVET6 led to the
change of the ESH–ESC reappraisal of 200910 with
a new systolic BP goal of <150 mmHg. Different to
this, the Canadian Hypertension Education Program
(CHEP)4 recommends to lower BP <140/90 mmHg
for all patients irrespectively of the presence or ab-
sence of ISH and the Swiss Society of Hypertension
(SSH)5 applies BP goals <150/x mmHg. The recently
published consensus document of the ACCF/AHA
201111 (Table 2) advises two treatment stratifications
for patients >80 years with corresponding TBP. Pulse
pressure >65 mmHg is strongly correlated with left
ventricular hypertrophy and heart failure. Although
pulse pressure calculation is helpful for risk stratifica-
tion in patients >60 years, the ESH–ESC8 does recom-
mend BP measurement preferably to pulse pressure
measurement for daily management.
BP control and combination therapy
Rates of BP control in primary care settings are re-
ported to fall around 35%. Up to 75% of patients in
the very elderly do not meet BP goals. As a result,
the huge number of patients requires multidrug ap-
proaches to reach appropriate goals.12 Combination
therapy appears to have the potential to improve poor
BP control and responder rates increase up to 70%13
due to an increase of compliance and persistence.2
Simplified formulations with high forgiveness factors14
might be useful in octogenarians+.
Aims of the survey
Due to rising costs, a sufficient management of octo-
genarians+ is essential and information about the quality
of treatment in primary care has a high public interest.
Because little data is available about the treatment of
octogenarians+ in Switzerland, the primary objectives of
this survey were to investigate/identify
 the target pulse pressure- and TBP attainment
(TBPA) according to the SSH,5 ESH–ESC8 and
CHEP4 (Table 2) guidelines,
 the amount of octogenarians+ who may benefit by
an intensified therapy approach (TBP <140 sys-
tolic according to ACCF/AHA 201111),
 the most commonly prescribed substances and
their combinations and
 differences in age-related prescribing behaviour of
GPs and TBPA of patients with regards to GPs
(i) subspecializations; (i) age and (iii) geographi-
cal location.
Secondarily, we investigated
 whether the combined therapy of ACEI/diuretics
and angiotensin receptor blocker (ARB)/diuretics
as well as CCB/diuretics is superior to any other
dual therapy,
 whether diuretics combined with BBs or with a
renin angiotensin-converting enzyme inhibitors
(RAAS-Is) lead to higher TBPA and
 the impact of single-pill combination compared to
dual free combination on TBPA.
Materials and methods
For this survey, 450 GPs were chosen randomly from
a list of all Swiss GPs and asked, in a letter, to include
every adult patient (>18 years) with diagnosed hyper-
tension into the survey who visited the doctor’s prac-
tice within 1 week. One hundred and fifty-seven GPs
with different specializations responded to this call,
performed by Healthworld Switzerland AG and sub-
mitted data of 4594 patients using a web database.
The selection of GPs was performed on the basis of
eight different postal code areas (Aargau, Basel,
Bern/Oberwallis, Graubu¨nden, Eastern-Switzerland,
Western-Switzerland, Central-Switzerland/Tessin and
Zurich/Thurgau) to ensure a representative statistic.
GPs were assigned in two groups according to their
specializations: (i) internal medicine and (ii) family
medicine. Eight hundred and seventy-seven patients
(23.6%) met the criteria to be treated and were of an
age >80 years.
Demographic information (age, sex, weight and
height), systolic/diastolic BP (assessed in sitting posi-
tion with either auscultatory or oscillatory method),
pulse pressure (>50, 50–64 and <64 mmHg) and heart
rate were recorded. GPs were asked to report the
presence of organ damage such as impaired renal
function, stroke, heart failure, myocardial infarction
(MI), atherosclerosis, left ventricular hypertrophy,
microalbuminuria (30–300 mg/24 hours) and increase
of serum creatinine (# up to 133 lmol/l and $ up to
124 lmol/l). Other clinical measurements were not re-
quired. Furthermore, we assessed risk factors includ-
ing diabetes mellitus, pack years of nicotine abuse,
dyslipidaemia [cholesterol >6.5 mmol/l, high-density
lipoprotein (HDL) <1.0 mmol/l, LDL >4.0 mmol/l, tri-
glyceride >1.7 mmol/l] and family history of cardiovas-
cular disease. Laboratory values were processed when
they were available (fasting glucose, total and HDL
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cholesterol, potassium, creatinine, triglyceride, urea).
For the documentation of the current therapy, substan-
ces or trademarks of both monotherapy and single-pill
combination were selected interactively. Data of daily
dosage and treatment duration were recorded using
three time categories (<3, 3–6 and >6 months) and
concomitant therapies could be mentioned (antidia-
betic therapy, aspirin or lipid-lowering therapy) when
applied. Patients were defined as diabetic if fasting
glucose levels exceeded 7 mmol/l or if antidiabetic
treatment was prescribed. GPs were asked to indicate
the founding year of their practice which was assessed
in three periods (1970–90, 1991–2000 and 2001–10)
and used as an indirect marker for their age. Descrip-
tive statistics (classical tests of hypotheses) were per-
formed for the subgroup of patients >80 years using
the software package R, version 2.12. Unpaired means
were compared using t-test and one-way ANOVA fol-
lowed by Bonferroni’s correction if means of more
than two groups were of interest. We compared di-
chotomous outcomes with chi-square test and com-
pared ranks nonparametricly with either using the
Mann–Whitney test or the Kruskal–Wallis test (with
Dunn’s post-test) for comparisons of more than two
groups. Correlations were calculated with Pearson’s
moment correlation. Patients’ characteristics for both
groups (<80 and >80 years) were analysed for compa-
rable reasons (Table 1). Due to the fact that the design
of this survey did not meet the definition of a clinical
study,15 no ethic committee approval was necessary
according to Swiss national law.16 Nevertheless, the
project was submitted to the ethical committee, Basel,
for confirmation and clearance. The design of the
questionnaire was created in cooperation with two
members of the SSH in order to collect implementable
information for future national recommendations and
to provide adherence to wording and units for meas-
urements used in the current SSH guidelines.
Primary results
Patients’ characteristics
Octogenarians+ showed more organ damages (71% ver-
sus 24.7%) than patients <79 years. One quarter of
octogenarians+ was detected with uncontrolled ISH,
which represents an increase of 9.5% compared to pa-
tients <79 years. Octogenarians+ were more likely to
be affected by heart failure (29.5% versus 8.3%), stroke
(14.1% versus 4.7%) and MI (29.5% versus 8.3%) than
patients <79 years (Table 1). On the other hand, less
patients were diagnosed with diabetes (–3.2%) and met-
abolic syndrome (–5.7%) in the subgroup of octo-
genarians+. The majority of octogenarians+ appeared
with Grade I hypertension or had high-normal BP.
Patients (8.1%) were treated optimally and showed sys-
tolic/diastolic BP <120/80 mmHg. Patients (11.4%) suf-
fered on Grades II or III hypertension (Fig. 1A). When
comparing patients from urban and rural areas, there
was no significant difference in age (P = 0.26), weight
(P = 0.47) and body mass index (BMI) (P = 0.67). How-
ever, a tendency towards more MI (P = 0.009) and
more strokes (P = 0.078) in rural areas could be sus-
pected. Significantly, more patients living (P = 0.044) in
the countryside were diagnosed with heart failure than
in the Swiss cities.
The distribution of pulse pressure and TBPA in the
background of various guideline recommendations
In total, 33.5% of all patients showed an elevated pulse
pressure >46 mmHg, while 18.8% had normal values
(<50 mmHg). Applying the SSH guidelines (<150/90
mmHg), 74.1% of patients attained TBP (Fig. 1D) and
53.1% of patients reached the goals (<140/90 mmHg)
of CHEP (Fig. 1B). In comparison, HYVET targets
(<150/80 mmHg) were reached by only 44.2% of
patients due to lower diastolic BP values (Fig. 1C).
Applying TPB <130/80 mmHg for patients with renal
impairment or diabetes mellitus, <150/90 mmHg for all
octogenarians+ with/without ISH resulted in a pooled
TBPA of 57.2%. In total, 35.1% of all patients reached
targets according to all three guidelines, while 25.9%
did not meet a single goal provided in the investigated
guidelines.
Intensified treatment
According to the ACCF/AHA 201111 recommenda-
tion, 15.3% of octogenarians+ attained TBP of 150/xx
mmHg with one or two substances (Fig. 1E) irrespec-
tive of their admission as single-pill therapy or dual
free combination. Therefore, these subjects qualified
for intensified treatment (TBP <140/xx mmHg). In to-
tal, 21.9% of octogenarians+ met BP goals of <150/xx
mmHg with more than two substances.
Distribution of applied substances and combinations. In
total, 85.9% of octogenarians+ were actively treated.
TABLE 1 Patients characteristics
Patients >80
years old
(n = 877)
Patients <80
years old
(n = 2843)
Sex: male/female (%) 36.4/63.6 54.4/45.6
Age (years) 84.8 (±3.9) 63.8 (±10.4)
Weight (kg) 70.8 (±13.3) 81.8 (±15.7)
Height (cm) 163.9 (±8.7) 169.1 (±8.8)
BMI (kg/m2) 26.3 (±4.2) 28.6 (±5.0)
BP
Systolic BP (mmHg) 137.9 (±16.4) 136.0 (±13.8)
Diastolic BP (mmHg) 77.2 (±10.1) 81.6 (±8.8)
Heart rate (BPM) 73.3 (±10.9) 73.0 (±10.1)
Concomitant cardiovascular diseases
MI (%) 13.3 10.2
Stroke (%) 14.1 4.7
Heart failure (%) 29.5 8.3
BMI, body mass index; BPM, beats per minute.
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Ninety-five per cent of all patients received a stable and
unchanged regime of therapy for more than 6 months.
Monotherapy was the most commonly used formulation
(diuretics: 27.2%, ACEIs: 20.2%). Dual single-pill com-
bination was administered with the second greatest fre-
quency, for which diuretic-based regimes with ARBs
(46.5%) and ACEIs (36.0%) were intensively chosen.
The amount of prescribed ARBs in dual single-pill com-
binations increased (Fig. 3B) by 16.8% compared to
dual free combination (Fig. 3A). The treatment ap-
proach using two single drugs was applied with the third
greatest frequency in this survey. The most common
combinations were BB/diuretics (25.3%) and ACEI/diu-
retics (15.6%). It is also remarkable that octogenarians+
received a relatively high amount of BBs (39.4%).
Interestingly, in dual single-pill combinations, the
amount of diuretics increased by 16.1% compared to
dual free combination (Fig. 3A and B). Furthermore,
there was a slight negative correlation for the use of
ACEIs (rpb = –0.11) and ARBs (rpb = –0.067) by age,
while for diuretics and BBs, no significant correlation
could be calculated.
Impact of working years on prescribing behaviour and
the influence of GPs’ characteristics on TBPA
GPs who founded their practices between 2000 and
2009 prescribed the lowest amount of ARBs (–5.6%)
and the highest amount of ACEIs (+3.9%) compared
to GPs who established their business between 1970
and 1989 (Fig. 2). The prescription of diuretics in-
creased 2.5% during this period of time. We identi-
fied a slightly positive association between an earlier
founding year of the practice and a higher responder
rate to our survey. GPs in urban areas prescribed sin-
gle-pill combinations more often (P = 0.003) than GPs
in rural areas of Switzerland. A similar tendency was
observed when the specialization of the GPs was ana-
lysed. Thus, GPs with a speciality for internal medicine
(GPint) recommended single-pill combinations more
often (P = 0.009) than their colleagues with a speciali-
zation for family medicine (GPfam), which was held by
60.2%. More than a half of all GPs were urbanely lo-
cated (<10 000 inhabitants), while 45% worked in rural
areas, where a lower density of GPint (23.3%) could be
found (GPint in urban areas: 42.9%). Similarly, there
were significantly more (P < 0.0001) GPfam in rural
areas. Our data show that there was no significant dif-
ference (P = 0.304) in TBPA comparing GPs working
in rural or urban areas (Fig. 1F).
A significant difference (P < 0.0001) could be de-
tected when comparing the speciality of GPs. GPint
obtained in 81.36% TBP, meanwhile GPfam reached
the goals for their patients in only 69.85% (Fig. 1G).
This was supported by a significant difference of
systolic BP (P < 0.0001; GPint 134 mmHg, GPfam
139 mmHg). Patients’ characteristics did not differ
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FIGURE 1 (A) Distribution of hypertension stages according to the guidelines of the SSH5—optimal (<120/180 mmHg), normal
(120–129/80–84 mmHg), high normal (130–139/85–89 mmHg), Stage I (140–159/90–99 mmHg), Stage II (160–179/100–109 mmHg),
Stage III (>180/>110 mmHg), TBPA according to (B) CHEP,4 (C) ESH–ESC,8 (D) SSH,5 (E) TBPA according to ACCF/AHA
with one or two substances, (F) differences in TBPASSH for urban and rural areas, (G) TBPASSH according to subspecialization of
GPs. SSH 2009, Swiss Society of Hypertension; ESC 2009, Reappraisal of European guidelines on hypertension management;
CHEP, The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension; ACCF/AHA
2011, Expert Consensus Document on Hypertension in the Elderly
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significantly for age (P = 0.84), weight (P = 0.40) and
BMI (P = 0.19) when comparing GPfam and GPfam.
MIs (P = 0.79), stroke (P = 0.079) and heart failure
(0.61) were similarly distributed within patients trea-
ted by GPs of both specializations. A slightly positive,
though not significant, correlation could be detected
between the age of GPs and TBPA.
Secondary results
Influence of recommended combinations in TBPA
according to SSH guidelines
Neither a RAAS-I alone nor any recommended combi-
nation of this class with a diuretic led to a significant
improved TBPA (ACEI/diuretic: 80.2%, ARB/diuretic:
73.6%) compared to other therapies. The use of CCBs
alone and in combination with diuretics (75.2%) also
had no impact in the same setting. Furthermore, there
was no significant higher TBPA (76.8% versus 71.0%)
between a diuretic-based combination with a RAAS-I
(ACEI/diuretic, ARB/diuretic) and a diuretic-based
combination with a BB.
The impact of single-pill combination on TBPA
No difference in TBPA between single-pill combina-
tion therapy and dual free combination therapy in
octogenarians+ could be detected. Surprisingly, there
was even a trend towards higher target attainments
with dual free combination. Patients treated consecu-
tively with dual free combinations showed a signifi-
cantly lower systolic BP (P = 0.035). Furthermore,
a higher amount of patients with heart failure (P <
0.0001), cardiac hypertrophy (P = 0.0009) and chronic
kidney disease (P = 0.0002) received combined ther-
apy with two separate pills.
Discussion
Because there is no conclusive analysis in Switzerland
that focuses on the treatment of the very elderly, this
is the first big investigation that offers insight into
how octogenarians+ are managed in primary care. In
addition, the problem of treatment quality according
to specialization has never been addressed before for
with this specific population.
Although the ESH–ESC 2007 stated clearly that the
benefit of antihypertensive treatment is still unclear8
and also in 2009,10 no obligation for treatment was
mentioned, our data show that 85.9% of octogenarians
received treatment. This result reflects the awareness
of GPs of changing evidence.
The difference (30%) between the ESH–ESC/
HYVET and SSH is caused by a higher diastolic value
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Ninety-five per cent of all patients received a stable and
unchanged regime of therapy for more than 6 months.
Monotherapy was the most commonly used formulation
(diuretics: 27.2%, ACEIs: 20.2%). Dual single-pill com-
bination was administered with the second greatest fre-
quency, for which diuretic-based regimes with ARBs
(46.5%) and ACEIs (36.0%) were intensively chosen.
The amount of prescribed ARBs in dual single-pill com-
binations increased (Fig. 3B) by 16.8% compared to
dual free combination (Fig. 3A). The treatment ap-
proach using two single drugs was applied with the third
greatest frequency in this survey. The most common
combinations were BB/diuretics (25.3%) and ACEI/diu-
retics (15.6%). It is also remarkable that octogenarians+
received a relatively high amount of BBs (39.4%).
Interestingly, in dual single-pill combinations, the
amount of diuretics increased by 16.1% compared to
dual free combination (Fig. 3A and B). Furthermore,
there was a slight negative correlation for the use of
ACEIs (rpb = –0.11) and ARBs (rpb = –0.067) by age,
while for diuretics and BBs, no significant correlation
could be calculated.
Impact of working years on prescribing behaviour and
the influence of GPs’ characteristics on TBPA
GPs who founded their practices between 2000 and
2009 prescribed the lowest amount of ARBs (–5.6%)
and the highest amount of ACEIs (+3.9%) compared
to GPs who established their business between 1970
and 1989 (Fig. 2). The prescription of diuretics in-
creased 2.5% during this period of time. We identi-
fied a slightly positive association between an earlier
founding year of the practice and a higher responder
rate to our survey. GPs in urban areas prescribed sin-
gle-pill combinations more often (P = 0.003) than GPs
in rural areas of Switzerland. A similar tendency was
observed when the specialization of the GPs was ana-
lysed. Thus, GPs with a speciality for internal medicine
(GPint) recommended single-pill combinations more
often (P = 0.009) than their colleagues with a speciali-
zation for family medicine (GPfam), which was held by
60.2%. More than a half of all GPs were urbanely lo-
cated (<10 000 inhabitants), while 45% worked in rural
areas, where a lower density of GPint (23.3%) could be
found (GPint in urban areas: 42.9%). Similarly, there
were significantly more (P < 0.0001) GPfam in rural
areas. Our data show that there was no significant dif-
ference (P = 0.304) in TBPA comparing GPs working
in rural or urban areas (Fig. 1F).
A significant difference (P < 0.0001) could be de-
tected when comparing the speciality of GPs. GPint
obtained in 81.36% TBP, meanwhile GPfam reached
the goals for their patients in only 69.85% (Fig. 1G).
This was supported by a significant difference of
systolic BP (P < 0.0001; GPint 134 mmHg, GPfam
139 mmHg). Patients’ characteristics did not differ
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significantly for age (P = 0.84), weight (P = 0.40) and
BMI (P = 0.19) when comparing GPfam and GPfam.
MIs (P = 0.79), stroke (P = 0.079) and heart failure
(0.61) were similarly distributed within patients trea-
ted by GPs of both specializations. A slightly positive,
though not significant, correlation could be detected
between the age of GPs and TBPA.
Secondary results
Influence of recommended combinations in TBPA
according to SSH guidelines
Neither a RAAS-I alone nor any recommended combi-
nation of this class with a diuretic led to a significant
improved TBPA (ACEI/diuretic: 80.2%, ARB/diuretic:
73.6%) compared to other therapies. The use of CCBs
alone and in combination with diuretics (75.2%) also
had no impact in the same setting. Furthermore, there
was no significant higher TBPA (76.8% versus 71.0%)
between a diuretic-based combination with a RAAS-I
(ACEI/diuretic, ARB/diuretic) and a diuretic-based
combination with a BB.
The impact of single-pill combination on TBPA
No difference in TBPA between single-pill combina-
tion therapy and dual free combination therapy in
octogenarians+ could be detected. Surprisingly, there
was even a trend towards higher target attainments
with dual free combination. Patients treated consecu-
tively with dual free combinations showed a signifi-
cantly lower systolic BP (P = 0.035). Furthermore,
a higher amount of patients with heart failure (P <
0.0001), cardiac hypertrophy (P = 0.0009) and chronic
kidney disease (P = 0.0002) received combined ther-
apy with two separate pills.
Discussion
Because there is no conclusive analysis in Switzerland
that focuses on the treatment of the very elderly, this
is the first big investigation that offers insight into
how octogenarians+ are managed in primary care. In
addition, the problem of treatment quality according
to specialization has never been addressed before for
with this specific population.
Although the ESH–ESC 2007 stated clearly that the
benefit of antihypertensive treatment is still unclear8
and also in 2009,10 no obligation for treatment was
mentioned, our data show that 85.9% of octogenarians
received treatment. This result reflects the awareness
of GPs of changing evidence.
The difference (30%) between the ESH–ESC/
HYVET and SSH is caused by a higher diastolic value
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in the SSH guidelines, which is responsible for the
increasing number of strokes and MI in the very
elderly.17 Although in this respect, ESH–ESC seems to
be applicable, the Swiss recommendation (<150/x
mmHg) reflects the fact that a systolic/diastolic BP of
<140/80 mmHg (CHEP) is difficult to achieve in the
very elderly. Furthermore, it was assumed after
FRAMINGHAM18 that impaired tissue perfusion in
the elderly requires a slightly higher systolic BP.
Even though values of <140/90 mmHg lead to
reduction of the cardiovascular risk in middle age
patients, it must be mentioned that only one trial has
been conducted with patients aged between 65 and 85
years that references this goal.19 Until now, there are
no studies that included octogenarians+ with Stage I hy-
pertension. As a result, the approach recommended by
ACCF/AHA 201111 may be considered the most cur-
rent and applicable one. Therefore, our data show that
15.3% of patients who reached TBP could benefit from
an intensified treatment by applying a TBP <140/xx
mmHg (even though the treatment of octogenarians+
in this survey was sufficient, according to SSH).
However, it should be noted that excessive lowering
of the BP can reduce life quality and increases the car-
diovascular risk. The International Verapamil - Tran-
dolapril Study (INVEST) showed that drops of the
diastolic target <65 mmHg led to a remarkable in-
crease in mortality. Because treatment not only affects
systolic BP and the diastolic value is often depen-
dently linked, the ACCF/AHA 2011 considers a sys-
tolic range between 140 and 150/xx mmHg. Therefore,
the unresolved problem remains that there is no rec-
ommendation for an appropriate diastolic value, al-
though it is evident that both systolic and diastolic
BPs have a similar impact on the incidence of strokes
and coronary events.20
The high number of patients with ISH in octo-
genarians+ (24.8%) in this survey is congruent with
TABLE 2 TBP and recommendations in different guidelines
Age ESH–ESC8 2007 ESH–ESC10 2009 CHEP4 2010 SSH5 2007/2008
Recommended
TBP
>65 Yrs TBP <140/90 mmHg
>80 Yrs Not mentioned TBP <150/xx mmHg
if SBP was <160
mmHg initially
TBP <140/90
mmHg
Not mentioned
Recommended
substances
>65 Yrs All substances (D, CCB,
ARB, ACEI, BB)
All substances,
no BB
All substances,
especially D, no BB
>80 Yrs Not mentioned
Mentioned trials/
substances applicable
for the elderly/very
elderly
>65 Yrs Not mentioned
>80 Years None HYVET6
(Indapamide/
ACEI)
None
Treatment generally
recommended?
>65 Yrs Yes
>80 Yrs Benefits of
treatment unclear,
continuation of
treatment if well
tolerated
Dependent on
health condition,
decision on
individual base
Not mentioned
Advices for ISH
(substances, TBP,
trials)
>65 Yrs D, CCB Not mentioned D, ARB, CCB,
TBP <140/90
mmHg
TBP <150/x mmHg
>80 Yrs Not mentioned
TBP applied in
data analysis
>80 Yrs
independently of
additional risk
factors/organ
damages:
<150/80 mmHg <140/80 mmHg <150/90 mmHg
ACCF/AHA 201111
Recommended TBP: x – 79 yrs: <140/xx mmHg. 80 – x yrs: <140 – 150/xx, Exceptions for octogenarians: SBD <140 mmHg if TBP <150 mmHg can
easily be obtained with one or two substances, SBD of <150 mmHg should be accepted if more than two substances are required, occurrence of
inacceptable side effects or DBP <65 mmHg
ESH–ESC 2007, Guidelines for the Management of Arterial Hypertension; ESH–ESC 2009, Reappraisal of European guidelines on hypertension
management; CHEP, The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension; SSH 2009,
Swiss Society of Hypertension; ACCF/AHA 2011, Expert Consensus Document on Hypertension in the Elderly; HYVET, HYpertension in the
Very Elderly Trial; yrs, years; CCB, calcium channel blocker; ARB, angiotensin receptor blocker; ACEI, angiotensin-converting enzyme inhibitor;
BB, beta-blocker; D, diuretic; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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data from the Hypertension and Diabetes Risk
Screening and Awareness trial.21 This might be due to
the fact that increased systolic BP values are often
misinterpreted as physiologic in the primary care. Un-
til now, there was a discrepancy among physicians on
the application of cut-off levels in patients with ISH,
as systolic BP of >160 mmHg has been previously clas-
sified as ISH and BP between 140 and 160 mmHg as
borderline ISH. Since 2003, several studies applied
systolic/diastolic BP cut-off levels >140/90 mmHg. The
CHEP guidelines reflect this paradigm shift (Table 2),
while the SSH recommends a slightly higher systolic
goal (<150/x mmHg). To this day, there are still no
‘general guidelines’ for the treatment of hypertension
in the very elderly. Although ACCF/AHA 2011 is a
consensus document, it remains an ‘expert document’
that has not been implemented in national guidelines.
The current situation appears with the following two
problems:
(1) Octogenarians+ are only randomly mentioned, or
they are included in the remarks about patients
>65 years. The only guidelines that currently pro-
vide extended information are the ESC–ESH 2009
reappraisal10 and the ACCF/AHA 2011. Goals ap-
plied in HYVET6 are advised to be applicable in
the very elderly; however, authors of the guide-
lines restrict their statements due to limited trans-
ferability of this trial to daily practice because
most of the enrolled subjects were in good health
without further co-morbidities, atypical for
octogenarians+.
(2) It is unclear how far additional risk factors must
be reflected in the treatment and result in even
lower TBP goals. We have shown the remarkable
difference in TBPA when applying the cut-off level
of 130/80 mmHg for high-risk patients. In the Car-
dio-Sis-study,22 lower event rates were recorded
with systolic TBP of <130 versus SBP <140 mmHg.
In contrast, however, the results of Action to Con-
trol Cardiovascular Risk is Diabetes trial23 yielded
no difference in event rates when either a systolic
BP of <120 or <140 mmHg was applied.
Pulse pressure increases continuously with age and
leads to an increased cardiovascular risk. Therefore, a
reduction of pulse pressure <65 mmHg is strongly
TABLE 3 BP control, target organ damage and drug prescription according to the specialization of practitioners (family medicine, internal medicine)
and to the location of the practitioners
Family medicine
(n = 534)
Internal medicine
(n = 295)
Pa Rural area
(n = 196)
Urban area
(n = 593)
Pa
Target BPSSH reached (%) 69.9 81.4 0.0003 72.3 75.4 0.30
SBP (mmHg) 139.7 (±17.4) 134.4 (±14.5) <0.0001 137.9 (±16.3) 137.9 (±16.5) 0.96
DBP (mmHg) 77.5 (±10.2) 76.6 (±9.7) 0.21 77.4 (±10.4) 77.1 (±9.8) 0.67
MI (%) 13.9 13.2 0.79 11.1 14.9 0.09
Stroke (%) 15.7 11.5 0.09 16.6 12.4 0.08
Heart failure (%) 30.5 28.8 0.61 33.2 26.9 0.04
Atherosclerosis 52.9 54.9 0.59 49.9 55.0 0.13
Cardiac hypertrophy (%) 23.4 27.8 0.16 33.2 26.9 0.04
Microalbuminuria (%) 13.5 13.6 0.97 13.0 14.5 0.52
Smoking (%)b 10.3 13.9 0.12 9.7 12.6 0.18
Premature CVD family (%) 37.6 45.7 0.02 40.9 40.9 0.97
Diabetes (%) 23.0 21.0 0.5 22.7 22.5 0.93
CKD (%) 24.7 21.0 0.23 21.9 25.4 0.23
Age (years) 84.8 (±3.9) 84.9 (±3.9) 0.84 84.6 (±3.8) 84.9 (±3.9) 0.25
Sex (female) (%) 65.2 60.7 0.19 67.3 61.0 0.06
BMI (kg/m2) 26.4 (±4.2) 25.9 (±4.3) 0.21 26.3 (±4.0) 26.2 (±4.3) 0.65
Mono therapy (%) 29.6 30.1 0.78 28.5 29.8 0.67
DFC therapy (%)c 54.6 39.3 0.009 58.7 38.8 0.0003
SPC therapy (%)c 45.3 60.7 0.009 41.3 61.2 0.0003
Triple therapy (%) 23.2 21.4 0.54 23.3 22.7 0.84
BB (%) 41.0 36.3 0.18 40.7 38.6 0.52
D (%) 68.5 68.8 0.94 67.6 70.2 0.42
CCB (%) 28.8 23.4 0.09 27.7 26.6 0.71
ACEI (%) 33.3 28.5 0.15 35.2 30.0 0.11
ARB (%) 33.7 42.7 0.01 33.8 38.6 0.15
DRI (%) 1.7 0.7 0.34 1.1 1.6 0.77
CKD, chronic kidney disease; CVD, cardiovascular disease; D, diuretic; DFC, dual free combination; DRI, direct renin inhibitor; SPC, single-pill
combination.
aP was calculated using chi-square test and t-test (SBP, DBP, age and BMI), respectively.
bJust actual smoking, we did not ask for smoking history.
cQuote of all patients treated with dual therapies (n = 326).
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in the SSH guidelines, which is responsible for the
increasing number of strokes and MI in the very
elderly.17 Although in this respect, ESH–ESC seems to
be applicable, the Swiss recommendation (<150/x
mmHg) reflects the fact that a systolic/diastolic BP of
<140/80 mmHg (CHEP) is difficult to achieve in the
very elderly. Furthermore, it was assumed after
FRAMINGHAM18 that impaired tissue perfusion in
the elderly requires a slightly higher systolic BP.
Even though values of <140/90 mmHg lead to
reduction of the cardiovascular risk in middle age
patients, it must be mentioned that only one trial has
been conducted with patients aged between 65 and 85
years that references this goal.19 Until now, there are
no studies that included octogenarians+ with Stage I hy-
pertension. As a result, the approach recommended by
ACCF/AHA 201111 may be considered the most cur-
rent and applicable one. Therefore, our data show that
15.3% of patients who reached TBP could benefit from
an intensified treatment by applying a TBP <140/xx
mmHg (even though the treatment of octogenarians+
in this survey was sufficient, according to SSH).
However, it should be noted that excessive lowering
of the BP can reduce life quality and increases the car-
diovascular risk. The International Verapamil - Tran-
dolapril Study (INVEST) showed that drops of the
diastolic target <65 mmHg led to a remarkable in-
crease in mortality. Because treatment not only affects
systolic BP and the diastolic value is often depen-
dently linked, the ACCF/AHA 2011 considers a sys-
tolic range between 140 and 150/xx mmHg. Therefore,
the unresolved problem remains that there is no rec-
ommendation for an appropriate diastolic value, al-
though it is evident that both systolic and diastolic
BPs have a similar impact on the incidence of strokes
and coronary events.20
The high number of patients with ISH in octo-
genarians+ (24.8%) in this survey is congruent with
TABLE 2 TBP and recommendations in different guidelines
Age ESH–ESC8 2007 ESH–ESC10 2009 CHEP4 2010 SSH5 2007/2008
Recommended
TBP
>65 Yrs TBP <140/90 mmHg
>80 Yrs Not mentioned TBP <150/xx mmHg
if SBP was <160
mmHg initially
TBP <140/90
mmHg
Not mentioned
Recommended
substances
>65 Yrs All substances (D, CCB,
ARB, ACEI, BB)
All substances,
no BB
All substances,
especially D, no BB
>80 Yrs Not mentioned
Mentioned trials/
substances applicable
for the elderly/very
elderly
>65 Yrs Not mentioned
>80 Years None HYVET6
(Indapamide/
ACEI)
None
Treatment generally
recommended?
>65 Yrs Yes
>80 Yrs Benefits of
treatment unclear,
continuation of
treatment if well
tolerated
Dependent on
health condition,
decision on
individual base
Not mentioned
Advices for ISH
(substances, TBP,
trials)
>65 Yrs D, CCB Not mentioned D, ARB, CCB,
TBP <140/90
mmHg
TBP <150/x mmHg
>80 Yrs Not mentioned
TBP applied in
data analysis
>80 Yrs
independently of
additional risk
factors/organ
damages:
<150/80 mmHg <140/80 mmHg <150/90 mmHg
ACCF/AHA 201111
Recommended TBP: x – 79 yrs: <140/xx mmHg. 80 – x yrs: <140 – 150/xx, Exceptions for octogenarians: SBD <140 mmHg if TBP <150 mmHg can
easily be obtained with one or two substances, SBD of <150 mmHg should be accepted if more than two substances are required, occurrence of
inacceptable side effects or DBP <65 mmHg
ESH–ESC 2007, Guidelines for the Management of Arterial Hypertension; ESH–ESC 2009, Reappraisal of European guidelines on hypertension
management; CHEP, The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension; SSH 2009,
Swiss Society of Hypertension; ACCF/AHA 2011, Expert Consensus Document on Hypertension in the Elderly; HYVET, HYpertension in the
Very Elderly Trial; yrs, years; CCB, calcium channel blocker; ARB, angiotensin receptor blocker; ACEI, angiotensin-converting enzyme inhibitor;
BB, beta-blocker; D, diuretic; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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data from the Hypertension and Diabetes Risk
Screening and Awareness trial.21 This might be due to
the fact that increased systolic BP values are often
misinterpreted as physiologic in the primary care. Un-
til now, there was a discrepancy among physicians on
the application of cut-off levels in patients with ISH,
as systolic BP of >160 mmHg has been previously clas-
sified as ISH and BP between 140 and 160 mmHg as
borderline ISH. Since 2003, several studies applied
systolic/diastolic BP cut-off levels >140/90 mmHg. The
CHEP guidelines reflect this paradigm shift (Table 2),
while the SSH recommends a slightly higher systolic
goal (<150/x mmHg). To this day, there are still no
‘general guidelines’ for the treatment of hypertension
in the very elderly. Although ACCF/AHA 2011 is a
consensus document, it remains an ‘expert document’
that has not been implemented in national guidelines.
The current situation appears with the following two
problems:
(1) Octogenarians+ are only randomly mentioned, or
they are included in the remarks about patients
>65 years. The only guidelines that currently pro-
vide extended information are the ESC–ESH 2009
reappraisal10 and the ACCF/AHA 2011. Goals ap-
plied in HYVET6 are advised to be applicable in
the very elderly; however, authors of the guide-
lines restrict their statements due to limited trans-
ferability of this trial to daily practice because
most of the enrolled subjects were in good health
without further co-morbidities, atypical for
octogenarians+.
(2) It is unclear how far additional risk factors must
be reflected in the treatment and result in even
lower TBP goals. We have shown the remarkable
difference in TBPA when applying the cut-off level
of 130/80 mmHg for high-risk patients. In the Car-
dio-Sis-study,22 lower event rates were recorded
with systolic TBP of <130 versus SBP <140 mmHg.
In contrast, however, the results of Action to Con-
trol Cardiovascular Risk is Diabetes trial23 yielded
no difference in event rates when either a systolic
BP of <120 or <140 mmHg was applied.
Pulse pressure increases continuously with age and
leads to an increased cardiovascular risk. Therefore, a
reduction of pulse pressure <65 mmHg is strongly
TABLE 3 BP control, target organ damage and drug prescription according to the specialization of practitioners (family medicine, internal medicine)
and to the location of the practitioners
Family medicine
(n = 534)
Internal medicine
(n = 295)
Pa Rural area
(n = 196)
Urban area
(n = 593)
Pa
Target BPSSH reached (%) 69.9 81.4 0.0003 72.3 75.4 0.30
SBP (mmHg) 139.7 (±17.4) 134.4 (±14.5) <0.0001 137.9 (±16.3) 137.9 (±16.5) 0.96
DBP (mmHg) 77.5 (±10.2) 76.6 (±9.7) 0.21 77.4 (±10.4) 77.1 (±9.8) 0.67
MI (%) 13.9 13.2 0.79 11.1 14.9 0.09
Stroke (%) 15.7 11.5 0.09 16.6 12.4 0.08
Heart failure (%) 30.5 28.8 0.61 33.2 26.9 0.04
Atherosclerosis 52.9 54.9 0.59 49.9 55.0 0.13
Cardiac hypertrophy (%) 23.4 27.8 0.16 33.2 26.9 0.04
Microalbuminuria (%) 13.5 13.6 0.97 13.0 14.5 0.52
Smoking (%)b 10.3 13.9 0.12 9.7 12.6 0.18
Premature CVD family (%) 37.6 45.7 0.02 40.9 40.9 0.97
Diabetes (%) 23.0 21.0 0.5 22.7 22.5 0.93
CKD (%) 24.7 21.0 0.23 21.9 25.4 0.23
Age (years) 84.8 (±3.9) 84.9 (±3.9) 0.84 84.6 (±3.8) 84.9 (±3.9) 0.25
Sex (female) (%) 65.2 60.7 0.19 67.3 61.0 0.06
BMI (kg/m2) 26.4 (±4.2) 25.9 (±4.3) 0.21 26.3 (±4.0) 26.2 (±4.3) 0.65
Mono therapy (%) 29.6 30.1 0.78 28.5 29.8 0.67
DFC therapy (%)c 54.6 39.3 0.009 58.7 38.8 0.0003
SPC therapy (%)c 45.3 60.7 0.009 41.3 61.2 0.0003
Triple therapy (%) 23.2 21.4 0.54 23.3 22.7 0.84
BB (%) 41.0 36.3 0.18 40.7 38.6 0.52
D (%) 68.5 68.8 0.94 67.6 70.2 0.42
CCB (%) 28.8 23.4 0.09 27.7 26.6 0.71
ACEI (%) 33.3 28.5 0.15 35.2 30.0 0.11
ARB (%) 33.7 42.7 0.01 33.8 38.6 0.15
DRI (%) 1.7 0.7 0.34 1.1 1.6 0.77
CKD, chronic kidney disease; CVD, cardiovascular disease; D, diuretic; DFC, dual free combination; DRI, direct renin inhibitor; SPC, single-pill
combination.
aP was calculated using chi-square test and t-test (SBP, DBP, age and BMI), respectively.
bJust actual smoking, we did not ask for smoking history.
cQuote of all patients treated with dual therapies (n = 326).
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recommended.2,8 In this survey, 66.4% of all patients at-
tained pulse pressure <65 mmHg, which is another indi-
cator for a sufficient treatment of BP in Switzerland.
Pulse pressure values are especially useful for the iden-
tification of patients with ISH although treatment ac-
cording to SBP and DBP remains standard of care.24
In this survey, physicians mostly prescribed substances
that are proven to be beneficial in outcome trials. Thus,
RAAS-I and diuretics were used most frequently irre-
spective of the formulation, as the guidelines especially
mention their gain in HYVET,6 SCOPE25 and LIVE.26
Although Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial27 provided evidence
for diuretics in patients with hypertension, Avoiding
Cardiovascular Events through Combination Therapy
in Patients Living with Systolic Hypertension28 showed
that diuretic-based treatment led to more cardiovascular
end points than CCBs in combination with ACEIs. The
long-term use of diuretics was evident in nearly all com-
binations of this survey.
BBs were prescribed to a high extent, considering
that SSH and CHEP guidelines do not recommend
their use. It cannot be clarified if these substances
were used exclusively for the treatment of hyperten-
sion or as secondary prevention of an MI. Also the
amount of diuretics/BB combination (25.3%) in dual
free combination remained high, although INVEST29
provided evidence that the administration of a thiazide
together with a BB led to an increase of cause-specific
and cardiovascular events. ARBs/diuretics were cho-
sen more often than ACEI/diuretics in dual single-pill
combination, which is in line with the fact that ARBs
are prescribed in Switzerland preferentially to ACEIs.
However, different to ACEIs, the administration of
ARBs correlated negatively with the age of the patient
and the founding year of the GP’s practice. Higher tol-
erability of side effects in this life decade, less consulta-
tions of GP’s and the habit to stick to long-term
treatment are possible explanations for this tendency.
Because of lower costs and high efficacy, younger GP’s
may consider a general adjustment of an ARB as un-
necessary. Interestingly, diuretics/RAAS-Is were used
more often in patients with uncontrolled ISH than
CCB/diuretics, which is recommended by the ESH–
ESC. This might be explained by MOSES,30 which
showed a lowering of stroke incidence by 25% when
using an ARB instead of a CCB.
Our results show that GPint obtained significantly
more often TBP compared to GPfam. This might be
explained by the fact that GPfam often refer patients
to other colleagues and specialists and maintain a man-
aging role in Switzerland. This may lead to a situation
of external and coexisting therapy plans that may have
an impact on patient’s compliance or result in the ac-
ceptance for higher BP due to a possible miscommuni-
cation. The distribution of prescription between GPint
and GPfam indicates restraint in GPfam for single-pill
combinations. Even though combined therapies can
increase responder rates, it must be taken into consid-
eration that a missed dose of a single-pill combination
may have a higher impact on BP control than the
non-adherence to one drug of a dual free combination.
Considering that 18% of octogenarians+ suffer from
cortical dementia, the risk of non-adherence to the
prescribed medication is elevated. Furthermore, it
must not be forgotten that the initial use of a single-
pill combination can result in a substantial drop in
BP. Therefore, it may can be assumed that GPfam pre-
fer a more steerable treatment approach which might
be the result of low patient adherence to visits. In the
other hand, GPint. tend to prescribe a more simplified
treatment regimen by the use of single-pill combina-
tion. However, our data showed that the TBPA be-
tween both administrations did not differ significantly.
Limitations
This investigation was a cross-sectional analysis. Thus,
we only detected uncontrolled ISH, and the actual
number of patients might be higher. The lack of differ-
ences in TBPA in patients treated with RAAS-Is- CCB
or diuretic-based combinations (Fig. 2E) compared to
any other combinations might be caused by the fact that
this survey was not designed to prove superiority of par-
ticular treatment regimes. As a result, the number of
patients in the different groups was small and the statis-
tical power insufficient. Physicians that participated in
this survey might have had a higher interest in the treat-
ment of arterial hypertension and thus may have
TABLE 4 Dual therapies: characteristics of octogenarians receiving
either a single-pill combination or a dual free combination
Single-pill
combination
(n = 172)
Dual free
combination
(n = 154)
Pa
SBP (mmHg) 138.5 (±14.7) 135.2 (±15.4) 0.035
DBP (mmHg) 78.9 (±8.6) 76.4 (±10.1) 0.53
Target BPSSH achieved (%) 75.0 79.2 0.43
MI (%) 5.8 10.4 0.15
Stroke (%) 16.3 12.3 0.35
Heart failure (%) 13.9 37.7 <0.0001
Atherosclerosis (%) 43.0 57.8 0.01
Cardiac hypertrophy (%) 15.7 32.2 0.0009
Microalbuminuria (%) 8.7 14.3 0.12
Smoking (%)b 9.9 13.6 0.31
Premature CVD family (%) 39.5 42.2 0.65
Diabetes (%) 19.2 22.1 0.58
CKD (%) 12.8 26.6 0.002
Age (years) 83.9 (±3.5) 85.5 (±4.2) 0.0002
Sex (female) (%) 56.9 69.5 0.02
BMI (kg/m2) 26.2 (±4.2) 26.2 (±4.4) 0.96
CKD, chronic kidney disease; CVD, cardiovascular disease; D, di-
uretic; DRI, direct renin inhibitor; DFC, dual free combination;
SPC, single-pill combination.
aP was calculated using chi-square test and t-test (SBP, DBP, age and
BMI), respectively.
bJust smoking, we did not ask for smoking history.
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treated with higher success. Comparing the ran-
domly chosen participants with regards to the postal
codes, there was a slight over-representation of individ-
uals from Basel and Graubu¨nden. Physicians from
Basel and Western-Switzerland included more patients
than the other postal code areas. However, because
there was no significant difference between responders
and non-responders (P = 0.8) in this survey with re-
gards to the geographical location, a selection bias
could be excluded. Despite these dissimilarities, there
was also no significant difference (P = 9.7) according to
responders and non-responders with regards to their
specialization. According to the Federal Office in Pub-
lic Health,15,16 study monitors are only allowed for clin-
ical trials. As the current investigation is a survey, it
could not be ensured that every patient who was visit-
ing GPs practice was included. However, adherence to
the procedure of this survey was maintained by a hono-
rarium which was paid after inclusion of at least one pa-
tient per GP.
Concluding remarks
Elderly patients are managed very efficiently in Swiss
primary care. Up to 30.8% of patients reached optimal
or normal BP and the actual number of treated pa-
tients was high (86%). Due to the strict adherence of
Swiss physicians to the combinations used in out-
come trials of elderly patients (D/ARBs, D/ACEIs),
octogenarians+ attained TBP between 44% and 74%.
However, the amount of TBPA differed widely based
on various guidelines. In the light of the compared
guideline recommendations, approximately one quar-
ter of octogenarians+ require improvement in their
treatment to reach TBP, while 15% of controlled pa-
tients could benefit from an intensified treatment with
a BP goal <140/xx mmHg, according to SSH guide-
lines. Drug therapy can be generally considered useful,
independent of patient’s age, which may prevent car-
diovascular events and contribute to a reduction of
public health system costs.
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recommended.2,8 In this survey, 66.4% of all patients at-
tained pulse pressure <65 mmHg, which is another indi-
cator for a sufficient treatment of BP in Switzerland.
Pulse pressure values are especially useful for the iden-
tification of patients with ISH although treatment ac-
cording to SBP and DBP remains standard of care.24
In this survey, physicians mostly prescribed substances
that are proven to be beneficial in outcome trials. Thus,
RAAS-I and diuretics were used most frequently irre-
spective of the formulation, as the guidelines especially
mention their gain in HYVET,6 SCOPE25 and LIVE.26
Although Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial27 provided evidence
for diuretics in patients with hypertension, Avoiding
Cardiovascular Events through Combination Therapy
in Patients Living with Systolic Hypertension28 showed
that diuretic-based treatment led to more cardiovascular
end points than CCBs in combination with ACEIs. The
long-term use of diuretics was evident in nearly all com-
binations of this survey.
BBs were prescribed to a high extent, considering
that SSH and CHEP guidelines do not recommend
their use. It cannot be clarified if these substances
were used exclusively for the treatment of hyperten-
sion or as secondary prevention of an MI. Also the
amount of diuretics/BB combination (25.3%) in dual
free combination remained high, although INVEST29
provided evidence that the administration of a thiazide
together with a BB led to an increase of cause-specific
and cardiovascular events. ARBs/diuretics were cho-
sen more often than ACEI/diuretics in dual single-pill
combination, which is in line with the fact that ARBs
are prescribed in Switzerland preferentially to ACEIs.
However, different to ACEIs, the administration of
ARBs correlated negatively with the age of the patient
and the founding year of the GP’s practice. Higher tol-
erability of side effects in this life decade, less consulta-
tions of GP’s and the habit to stick to long-term
treatment are possible explanations for this tendency.
Because of lower costs and high efficacy, younger GP’s
may consider a general adjustment of an ARB as un-
necessary. Interestingly, diuretics/RAAS-Is were used
more often in patients with uncontrolled ISH than
CCB/diuretics, which is recommended by the ESH–
ESC. This might be explained by MOSES,30 which
showed a lowering of stroke incidence by 25% when
using an ARB instead of a CCB.
Our results show that GPint obtained significantly
more often TBP compared to GPfam. This might be
explained by the fact that GPfam often refer patients
to other colleagues and specialists and maintain a man-
aging role in Switzerland. This may lead to a situation
of external and coexisting therapy plans that may have
an impact on patient’s compliance or result in the ac-
ceptance for higher BP due to a possible miscommuni-
cation. The distribution of prescription between GPint
and GPfam indicates restraint in GPfam for single-pill
combinations. Even though combined therapies can
increase responder rates, it must be taken into consid-
eration that a missed dose of a single-pill combination
may have a higher impact on BP control than the
non-adherence to one drug of a dual free combination.
Considering that 18% of octogenarians+ suffer from
cortical dementia, the risk of non-adherence to the
prescribed medication is elevated. Furthermore, it
must not be forgotten that the initial use of a single-
pill combination can result in a substantial drop in
BP. Therefore, it may can be assumed that GPfam pre-
fer a more steerable treatment approach which might
be the result of low patient adherence to visits. In the
other hand, GPint. tend to prescribe a more simplified
treatment regimen by the use of single-pill combina-
tion. However, our data showed that the TBPA be-
tween both administrations did not differ significantly.
Limitations
This investigation was a cross-sectional analysis. Thus,
we only detected uncontrolled ISH, and the actual
number of patients might be higher. The lack of differ-
ences in TBPA in patients treated with RAAS-Is- CCB
or diuretic-based combinations (Fig. 2E) compared to
any other combinations might be caused by the fact that
this survey was not designed to prove superiority of par-
ticular treatment regimes. As a result, the number of
patients in the different groups was small and the statis-
tical power insufficient. Physicians that participated in
this survey might have had a higher interest in the treat-
ment of arterial hypertension and thus may have
TABLE 4 Dual therapies: characteristics of octogenarians receiving
either a single-pill combination or a dual free combination
Single-pill
combination
(n = 172)
Dual free
combination
(n = 154)
Pa
SBP (mmHg) 138.5 (±14.7) 135.2 (±15.4) 0.035
DBP (mmHg) 78.9 (±8.6) 76.4 (±10.1) 0.53
Target BPSSH achieved (%) 75.0 79.2 0.43
MI (%) 5.8 10.4 0.15
Stroke (%) 16.3 12.3 0.35
Heart failure (%) 13.9 37.7 <0.0001
Atherosclerosis (%) 43.0 57.8 0.01
Cardiac hypertrophy (%) 15.7 32.2 0.0009
Microalbuminuria (%) 8.7 14.3 0.12
Smoking (%)b 9.9 13.6 0.31
Premature CVD family (%) 39.5 42.2 0.65
Diabetes (%) 19.2 22.1 0.58
CKD (%) 12.8 26.6 0.002
Age (years) 83.9 (±3.5) 85.5 (±4.2) 0.0002
Sex (female) (%) 56.9 69.5 0.02
BMI (kg/m2) 26.2 (±4.2) 26.2 (±4.4) 0.96
CKD, chronic kidney disease; CVD, cardiovascular disease; D, di-
uretic; DRI, direct renin inhibitor; DFC, dual free combination;
SPC, single-pill combination.
aP was calculated using chi-square test and t-test (SBP, DBP, age and
BMI), respectively.
bJust smoking, we did not ask for smoking history.
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treated with higher success. Comparing the ran-
domly chosen participants with regards to the postal
codes, there was a slight over-representation of individ-
uals from Basel and Graubu¨nden. Physicians from
Basel and Western-Switzerland included more patients
than the other postal code areas. However, because
there was no significant difference between responders
and non-responders (P = 0.8) in this survey with re-
gards to the geographical location, a selection bias
could be excluded. Despite these dissimilarities, there
was also no significant difference (P = 9.7) according to
responders and non-responders with regards to their
specialization. According to the Federal Office in Pub-
lic Health,15,16 study monitors are only allowed for clin-
ical trials. As the current investigation is a survey, it
could not be ensured that every patient who was visit-
ing GPs practice was included. However, adherence to
the procedure of this survey was maintained by a hono-
rarium which was paid after inclusion of at least one pa-
tient per GP.
Concluding remarks
Elderly patients are managed very efficiently in Swiss
primary care. Up to 30.8% of patients reached optimal
or normal BP and the actual number of treated pa-
tients was high (86%). Due to the strict adherence of
Swiss physicians to the combinations used in out-
come trials of elderly patients (D/ARBs, D/ACEIs),
octogenarians+ attained TBP between 44% and 74%.
However, the amount of TBPA differed widely based
on various guidelines. In the light of the compared
guideline recommendations, approximately one quar-
ter of octogenarians+ require improvement in their
treatment to reach TBP, while 15% of controlled pa-
tients could benefit from an intensified treatment with
a BP goal <140/xx mmHg, according to SSH guide-
lines. Drug therapy can be generally considered useful,
independent of patient’s age, which may prevent car-
diovascular events and contribute to a reduction of
public health system costs.
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